Gynocare update
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , , , , , , , , , , , , , , , , , , , , , , , , , , , , |
Tipo de documento: | Artigo |
Idioma: | eng |
Título da fonte: | Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
Texto Completo: | http://hdl.handle.net/10362/111177 |
Resumo: | More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on retrospective studies, expert opinion, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges by creating a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide. |
id |
RCAP_e7c1c53e8bf3a5d463e6a8b4310104a3 |
---|---|
oai_identifier_str |
oai:run.unl.pt:10362/111177 |
network_acronym_str |
RCAP |
network_name_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository_id_str |
7160 |
spelling |
Gynocare updateModern strategies to improve diagnosis and treatment of rare gynecologic tumors—current challenges and future directionsBiobankingCancer stem cellsCirculating tumor-specific markersPersonalized medicineRare gynecologic tumorsTheranosticsOncologyCancer ResearchSDG 3 - Good Health and Well-beingMore than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on retrospective studies, expert opinion, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges by creating a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide.NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM)RUNDi Fiore, RiccardoSuleiman, SherifEllul, BridgetO’toole, Sharon A.Savona-Ventura, CharlesFelix, AnaNapolioni, ValerioConlon, Neil T.Erson-Bensan, Ayse ElifKahramanoglu, IlkerAzzopardi, Miriam J.Dalmas, MiriamCalleja, NevilleBrincat, Mark R.Muscat-Baron, YvesSabol, MajaDimitrievska, VeraYordanov, AngelVasileva-Slaveva, Marielavon Brockdorff, KristelleMicallef, Rachel A.Kubelac, PaulAchimas-Cadariu, PatriciuVlad, CatalinTzortzatou, OlgaPoka, RobertGiordano, AntonioFelice, AlexReed, NicholasHerrington, C. SimonFaraggi, DavidCalleja-Agius, Jean2021-02-02T23:39:25Z2021-022021-02-01T00:00:00Zinfo:eu-repo/semantics/publishedVersioninfo:eu-repo/semantics/article14application/pdfhttp://hdl.handle.net/10362/111177eng2072-6694PURE: 27834162https://doi.org/10.3390/cancers13030493info:eu-repo/semantics/openAccessreponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos)instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãoinstacron:RCAAP2024-03-11T04:54:59Zoai:run.unl.pt:10362/111177Portal AgregadorONGhttps://www.rcaap.pt/oai/openaireopendoar:71602024-03-20T03:41:49.279068Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informaçãofalse |
dc.title.none.fl_str_mv |
Gynocare update Modern strategies to improve diagnosis and treatment of rare gynecologic tumors—current challenges and future directions |
title |
Gynocare update |
spellingShingle |
Gynocare update Di Fiore, Riccardo Biobanking Cancer stem cells Circulating tumor-specific markers Personalized medicine Rare gynecologic tumors Theranostics Oncology Cancer Research SDG 3 - Good Health and Well-being |
title_short |
Gynocare update |
title_full |
Gynocare update |
title_fullStr |
Gynocare update |
title_full_unstemmed |
Gynocare update |
title_sort |
Gynocare update |
author |
Di Fiore, Riccardo |
author_facet |
Di Fiore, Riccardo Suleiman, Sherif Ellul, Bridget O’toole, Sharon A. Savona-Ventura, Charles Felix, Ana Napolioni, Valerio Conlon, Neil T. Erson-Bensan, Ayse Elif Kahramanoglu, Ilker Azzopardi, Miriam J. Dalmas, Miriam Calleja, Neville Brincat, Mark R. Muscat-Baron, Yves Sabol, Maja Dimitrievska, Vera Yordanov, Angel Vasileva-Slaveva, Mariela von Brockdorff, Kristelle Micallef, Rachel A. Kubelac, Paul Achimas-Cadariu, Patriciu Vlad, Catalin Tzortzatou, Olga Poka, Robert Giordano, Antonio Felice, Alex Reed, Nicholas Herrington, C. Simon Faraggi, David Calleja-Agius, Jean |
author_role |
author |
author2 |
Suleiman, Sherif Ellul, Bridget O’toole, Sharon A. Savona-Ventura, Charles Felix, Ana Napolioni, Valerio Conlon, Neil T. Erson-Bensan, Ayse Elif Kahramanoglu, Ilker Azzopardi, Miriam J. Dalmas, Miriam Calleja, Neville Brincat, Mark R. Muscat-Baron, Yves Sabol, Maja Dimitrievska, Vera Yordanov, Angel Vasileva-Slaveva, Mariela von Brockdorff, Kristelle Micallef, Rachel A. Kubelac, Paul Achimas-Cadariu, Patriciu Vlad, Catalin Tzortzatou, Olga Poka, Robert Giordano, Antonio Felice, Alex Reed, Nicholas Herrington, C. Simon Faraggi, David Calleja-Agius, Jean |
author2_role |
author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author author |
dc.contributor.none.fl_str_mv |
NOVA Medical School|Faculdade de Ciências Médicas (NMS|FCM) RUN |
dc.contributor.author.fl_str_mv |
Di Fiore, Riccardo Suleiman, Sherif Ellul, Bridget O’toole, Sharon A. Savona-Ventura, Charles Felix, Ana Napolioni, Valerio Conlon, Neil T. Erson-Bensan, Ayse Elif Kahramanoglu, Ilker Azzopardi, Miriam J. Dalmas, Miriam Calleja, Neville Brincat, Mark R. Muscat-Baron, Yves Sabol, Maja Dimitrievska, Vera Yordanov, Angel Vasileva-Slaveva, Mariela von Brockdorff, Kristelle Micallef, Rachel A. Kubelac, Paul Achimas-Cadariu, Patriciu Vlad, Catalin Tzortzatou, Olga Poka, Robert Giordano, Antonio Felice, Alex Reed, Nicholas Herrington, C. Simon Faraggi, David Calleja-Agius, Jean |
dc.subject.por.fl_str_mv |
Biobanking Cancer stem cells Circulating tumor-specific markers Personalized medicine Rare gynecologic tumors Theranostics Oncology Cancer Research SDG 3 - Good Health and Well-being |
topic |
Biobanking Cancer stem cells Circulating tumor-specific markers Personalized medicine Rare gynecologic tumors Theranostics Oncology Cancer Research SDG 3 - Good Health and Well-being |
description |
More than 50% of all gynecologic tumors can be classified as rare (defined as an incidence of ≤6 per 100,000 women) and usually have a poor prognosis owing to delayed diagnosis and treatment. In contrast to almost all other common solid tumors, the treatment of rare gynecologic tumors (RGT) is often based on retrospective studies, expert opinion, or extrapolation from other tumor sites with similar histology, leading to difficulty in developing guidelines for clinical practice. Currently, gynecologic cancer research, due to distinct scientific and technological challenges, is lagging behind. Moreover, the overall efforts for addressing these challenges are fragmented across different European countries and indeed, worldwide. The GYNOCARE, COST Action CA18117 (European Network for Gynecological Rare Cancer Research) programme aims to address these challenges by creating a unique network between key stakeholders covering distinct domains from concept to cure: basic research on RGT, biobanking, bridging with industry, and setting up the legal and regulatory requirements for international innovative clinical trials. On this basis, members of this COST Action, (Working Group 1, “Basic and Translational Research on Rare Gynecological Cancer”) have decided to focus their future efforts on the development of new approaches to improve the diagnosis and treatment of RGT. Here, we provide a brief overview of the current state-of-the-art and describe the goals of this COST Action and its future challenges with the aim to stimulate discussion and promote synergy across scientists engaged in the fight against this rare cancer worldwide. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-02-02T23:39:25Z 2021-02 2021-02-01T00:00:00Z |
dc.type.status.fl_str_mv |
info:eu-repo/semantics/publishedVersion |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
http://hdl.handle.net/10362/111177 |
url |
http://hdl.handle.net/10362/111177 |
dc.language.iso.fl_str_mv |
eng |
language |
eng |
dc.relation.none.fl_str_mv |
2072-6694 PURE: 27834162 https://doi.org/10.3390/cancers13030493 |
dc.rights.driver.fl_str_mv |
info:eu-repo/semantics/openAccess |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
14 application/pdf |
dc.source.none.fl_str_mv |
reponame:Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) instname:Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação instacron:RCAAP |
instname_str |
Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
instacron_str |
RCAAP |
institution |
RCAAP |
reponame_str |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
collection |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) |
repository.name.fl_str_mv |
Repositório Científico de Acesso Aberto de Portugal (Repositórios Cientìficos) - Agência para a Sociedade do Conhecimento (UMIC) - FCT - Sociedade da Informação |
repository.mail.fl_str_mv |
|
_version_ |
1799138030964965376 |